BioCryst Tax Provision from 2010 to 2024

BCRX Stock  USD 7.60  0.11  1.47%   
BioCryst Pharmaceuticals Tax Provision yearly trend continues to be fairly stable with very little volatility. Tax Provision is likely to outpace its year average in 2024. Tax Provision is the amount set aside by BioCryst Pharmaceuticals to cover any estimated taxes for the current period. It reflects BioCryst Pharmaceuticals' expected tax liabilities. View All Fundamentals
 
Tax Provision  
First Reported
2010-12-31
Previous Quarter
1.8 M
Current Value
1.9 M
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 113.7 M or Selling General Administrative of 209.5 M, as well as many indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Days Sales Outstanding of 59.59. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

Latest BioCryst Pharmaceuticals' Tax Provision Growth Pattern

Below is the plot of the Tax Provision of BioCryst Pharmaceuticals over the last few years. It is the amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities. BioCryst Pharmaceuticals' Tax Provision historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Tax Provision10 Years Trend
Slightly volatile
   Tax Provision   
       Timeline  

BioCryst Tax Provision Regression Statistics

Arithmetic Mean578,255
Geometric Mean0.00
Coefficient Of Variation174.97
Mean Deviation848,107
Median0.00
Standard Deviation1,011,756
Sample Variance1T
Range2.7M
R-Value0.74
Mean Square Error503.9B
R-Squared0.54
Significance0
Slope166,696
Total Sum of Squares14.3T

BioCryst Tax Provision History

20241.9 M
20231.8 M
20222.7 M
20212.3 M

About BioCryst Pharmaceuticals Financial Statements

BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' Tax Provision, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Tax Provision1.8 M1.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.